EGFR and non-small cell lung carcinoma: We proved that AXL was the target of NPS1034 for the sensitization of EGFR-mutated NSCLC cells to osimertinib using wild-type AXL overexpression system in PC-9 cells (Supplementary Figure 9A, 9B).